Research Collaboration with UNSW for Coronary Artery Disease
Filed with ASX · · 2 pages · English
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHD
- Cynatas MSCs Effective in Model of Diabetic Wounds
- $5.2m placement of shares to Fidelity International
- Enrolment Completed in Cynatas Phase 1 Clinical Trial
- Notice of Allowance from EPO for Patent Application
Later from Cynata Therapeutics
- Positive 28-day Clinical Trial Data in Cohort B
- Product Development Program Update & Investor Presentation
- Cynata Enters Development Partnership with RCSI
- June 2018 Quarterly Report
- Cymerus MSCs improve cardiac recovery in preclinical study
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics